Usefulness of Cardiopulmonary Exercise Testing for Cardiovascular Risk Estimation and Frailty Assessment in Liver Transplant Candidates

CompletedOBSERVATIONAL
Enrollment

54

Participants

Timeline

Start Date

September 25, 2020

Primary Completion Date

May 31, 2022

Study Completion Date

May 31, 2022

Conditions
Cardiovascular Diseases+Liver Transplantation
Interventions
DEVICE

Cardiopulmonary exercise testing

Subjects will perform cardiopulmonary exercise testing which consists of biking on a cycle ergometer (recumbant stationary bicycle) while breathing through a mouthpiece or mask to measure the oxygen and carbon dioxide in the subject's breath. We will also do impedance cardiography, an FDA-approved test to check how the heart functions during exercise. For this test we will attach 6 electrodes (total) to the chest and back (similar to an EKG), so that we can measure the quantity of blood coming out of the heart on every heartbeat. Each evaluation will also include cardiac testing looking for coronary artery disease (CAD).

Trial Locations (2)

15213

University of Pittsburgh Medical Center, Pittsburgh

85054

Mayo Clinic Arizona, Phoenix

All Listed Sponsors
lead

Andres Duarte-Rojo

OTHER

NCT04543825 - Usefulness of Cardiopulmonary Exercise Testing for Cardiovascular Risk Estimation and Frailty Assessment in Liver Transplant Candidates | Biotech Hunter | Biotech Hunter